The present invention relates to compounds having agonist activity in receptors of GLP-1 (glucagon like peptide 1) and GLP-2 (glucagon like peptide 2). This compound is particularly used in the prevention or treatment of intestinal damage and dysfunction, prevention of weight, and prevention or ...
[1] 《多肽药物制备工艺研究进展》[2] 《Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP》[3] 《Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing》文中数据及参数均由企业提...
3. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonist. Front Endocrinol, 2024, 15: 1431292. 4. Informa数据库, 检索日期: 2024年11月15日. 5. 药渡数据库, 检索日期: 2024年11月15日. ...
1. Zhao L, et al. 1861-LB#Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults: A Phase 2 Trial. Presented at ADA 2024. 2. Nauck, et al. Lancet Diabetes Endocrinol. 201...
(生物谷Bioon.com) 参考文献 Eun Ran Kim et al. A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome. Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or
2.A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 wherein:X2 is Aib;X5 is S or T;X7 is S or T;X8 is S or D;X10 is L;X11 is A or S;X15 is D or EX16 is E or G;X17 is Q or K;X19 is A or S;X20 is R;X21 is D or E;X24 is A, N...
When would I need to take a GLP-1 agonist? Healthcare providersprescribeGLP-1 agonists for two conditions: Type 2 diabetes and obesity. prescribe:开药 GLP-1 agonists for Type 2 diabetes The FDA approves the use of GLP-1 agonists to help manage Type 2 diabetes (T2D). This is because G...
资料来源：Drug Des Devel Ther. Lijing Wang，《Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP》，X技术，国知局，华福研究所 替尔泊肽结构设计基于GLP-1、GIP及艾塞那肽的部分结构、以及增加的特有氨基酸（其中Aib是非天然氨基酸），合成...
为了解决这个问题,科学家们发明了一种叫做GLP-1受体激动剂(GLP-1 receptor agonist)的药物。这种药物能够模拟GLP-1的结构和功能,与人体内的GLP-1受体结合,从而发挥类似于GLP-1的作用。与GLP-1不同的是,GLP-1受体激动剂具有更长的半衰期,能够在人体内持续存在和发挥效果。因此,GLP-1受体激动剂能够有效地降低血糖...